Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
Tenaya Therapeutics (NASDAQ: TNYA), a clinical-stage biotech company focused on developing curative therapies for heart disease, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's CEO, Faraz Ali, will engage in a fireside chat on Tuesday, August 12, 2025 at 11:30 am ET.
Investors can access the live webcast through Tenaya's website's Investor section, with a replay available for approximately 30 days after the event.
Tenaya Therapeutics (NASDAQ: TNYA), una società biotecnologica in fase clinica focalizzata sullo sviluppo di terapie curative per le malattie cardiache, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Crescita di Canaccord Genuity. Il CEO dell'azienda, Faraz Ali, parteciperà a una conversazione informale martedì 12 agosto 2025 alle 11:30 ET.
Gli investitori potranno seguire la diretta streaming attraverso la sezione Investor del sito web di Tenaya, con una replica disponibile per circa 30 giorni dopo l'evento.
Tenaya Therapeutics (NASDAQ: TNYA), una empresa biotecnológica en etapa clínica dedicada al desarrollo de terapias curativas para enfermedades cardíacas, ha anunciado su participación en la 45ª Conferencia Anual de Crecimiento de Canaccord Genuity. El CEO de la compañía, Faraz Ali, participará en una charla informal el martes 12 de agosto de 2025 a las 11:30 am ET.
Los inversores podrán acceder a la transmisión en vivo a través de la sección de inversores del sitio web de Tenaya, con una repetición disponible durante aproximadamente 30 días después del evento.
Tenaya Therapeutics (NASDAQ: TNYA)는 심장 질환 치료제를 개발하는 임상 단계 바이오테크 회사로, 다가오는 Canaccord Genuity 제45회 연례 성장 컨퍼런스에 참여한다고 발표했습니다. 회사의 CEO인 Faraz Ali는 2025년 8월 12일 화요일 오전 11시 30분(동부 시간)에 화상 대화에 참여할 예정입니다.
투자자들은 Tenaya 웹사이트의 투자자 섹션을 통해 생중계에 접속할 수 있으며, 행사 후 약 30일간 다시보기도 제공됩니다.
Tenaya Therapeutics (NASDAQ : TNYA), une société biotechnologique en phase clinique spécialisée dans le développement de thérapies curatives pour les maladies cardiaques, a annoncé sa participation à la 45e conférence annuelle sur la croissance de Canaccord Genuity. Le PDG de l'entreprise, Faraz Ali, participera à une discussion informelle le mardi 12 août 2025 à 11h30 ET.
Les investisseurs pourront accéder à la diffusion en direct via la section Investisseurs du site web de Tenaya, avec un replay disponible pendant environ 30 jours après l'événement.
Tenaya Therapeutics (NASDAQ: TNYA), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung heilender Therapien für Herzkrankheiten spezialisiert hat, hat seine Teilnahme an der bevorstehenden 45. jährlichen Wachstumskonferenz von Canaccord Genuity angekündigt. Der CEO des Unternehmens, Faraz Ali, wird am Dienstag, den 12. August 2025 um 11:30 Uhr ET an einem Gespräch teilnehmen.
Investoren können das Live-Webcast über den Investor-Bereich auf der Website von Tenaya verfolgen; eine Aufzeichnung steht etwa 30 Tage nach der Veranstaltung zur Verfügung.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at 11:30 am ET.
The live webcast of the fireside chat may be accessed from the Investors section of Tenaya’s website. An archived replay will be available on the Tenaya website for approximately 30 days following the live event.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
FAQ
When is Tenaya Therapeutics (TNYA) presenting at the Canaccord Genuity Conference?
How can investors access Tenaya Therapeutics' (TNYA) Canaccord conference presentation?
Who will represent Tenaya Therapeutics (TNYA) at the Canaccord Genuity Conference?
What is Tenaya Therapeutics' (TNYA) main business focus?
